OpenAI Launches GPT-Rosalind, a Specialized AI Model for Life Sciences

OpenAI on Thursday launched GPT-Rosalind, a specialized artificial intelligence model designed for life sciences research, marking the company’s most significant push into domain-specific scientific AI tools.

The model, named after British chemist Rosalind Franklin, targets applications in drug discovery, genomics analysis and protein reasoning. OpenAI said the system was trained to handle the complex reasoning chains required in biological and chemical research.

GPT-Rosalind represents a departure from OpenAI’s general-purpose model strategy. Rather than building a single system capable of broad tasks, the company developed a model optimized for the specific demands of life sciences workflows, where accuracy and domain expertise are critical.

The release comes as pharmaceutical companies and research institutions increasingly adopt AI tools to accelerate drug development timelines and reduce costs. Industry analysts estimate the AI-driven drug discovery market could exceed $4 billion by 2027.

OpenAI said the model can assist researchers with analyzing genomic sequences, predicting protein structures and interactions, evaluating potential drug candidates, and synthesizing findings from scientific literature. The company indicated the model underwent specialized evaluation against established life sciences benchmarks.

The move places OpenAI in more direct competition with companies already operating in the scientific AI space, including Google DeepMind, whose AlphaFold system has been widely adopted for protein structure prediction, and startups such as Recursion Pharmaceuticals and Insilico Medicine.

OpenAI did not immediately disclose pricing details or whether GPT-Rosalind would be available through its existing API infrastructure or as a standalone product.

The launch follows a broader industry trend toward vertical AI models tailored to specific professional domains, including legal analysis, financial modeling and healthcare diagnostics. Several major AI labs have signaled intentions to develop specialized systems rather than relying solely on general-purpose models.

OpenAI has not yet announced partnerships with specific pharmaceutical companies or research institutions for the initial rollout.